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Abstract 
Plasminogen activator inhibitor-1 (PAl-1) is a primary endogenous inhibitor of tissue-type plasminogen activator (t-PA). In this study, 
we examined the effects of oversulfated fucoidan (OSF) derivatives and heparin on lipopolysaccharide (LPS)-induced release of PAI-1 
antigen from cultured human umbilical vein endothelial cells (HUVEC). Addition of LPS (10 /xg/ml) enhanced the release of PAI-1 by 
HUVEC but not of t-PA antigen. At 18 h, a 2.4-fold increase in the extracellular PAI-1 level was observed. The increased PAI-1 level 
was reduced to control evel by the simultaneous addition of 10/xg/ml of OSF or heparin. The suppressive effect of native fucoidan was 
negligible. We also examined the molecular size effect of OSF, using 10-20, 20-40, and 40-60 kDa fragments. The result indicated that 
these fragments were effectNe as well as the 100-130 kDa form of OSF, hence suggesting an important role of the degree of sulfation. 
Interleukin-1/3 (IL-lf l)  is a potent inducer of PAI-I in cultured HUVEC. Heparin, OSF, and its fragments did not suppress the 
IL-l/3-induced release of PAI-I antigen. Treatment of HUVEC with heparitinase or monoclonal antibody against heparan sulfate 
proteoglycan (HSPG) resulted in a complete loss of its ability to enhance PAI-I release in response to LPS stimulation, while the 
chondroitinase ABC treatment hardly affected the PAl-1 production. These results uggest that HSPG is involved in the initial binding of 
LPS to HUVEC. The suppressive effects of OSF and heparin on LPS-induced PAI-1 release may result from the inhibition of LPS 
binding to the cell surface HSPG. 
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1. Introduction 
Vascular endothelial cells play an active role in the 
regulation of fibrinolysis through the synthesis and secre- 
tion of both tissue-type plasminogen activator (t-PA) and 
plasminogen activator inhibitor-1 (PAl- l ) .  The vascular 
endothelium is a target of endotoxic lipopolysaccharide 
(LPS) during the course of Gram-negative infections. LPS 
stimulation of cultured human endothelial cells resulted in 
Abbreviations: t-PA, tissue-type plasminogen activator; PAl-l, plas- 
minogen activator inhibitor-l; LPS, lipopolysaccharide; DIC, dissemi- 
nated intravascular coagulation; OSF, oversulfated fucoidan; HUVEC, 
human umbilical vein endothelial cells; HSPG, heparan sulfate proteogly- 
can; mAb, monoclonal ntibody; IL-lfl, interleukin-l/3; DMEM, Dul- 
becco's modified Eagle's medium; ELISA, enzyme-linked immuno- 
sorbent assay. 
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an enhanced rate of accumulation of PAI-1 activity [1,2] 
but not of t-PA antigen [1] in the medium. In patients with 
septicemia, enhanced levels of PAI- I  were observed in 
plasma [2]. These findings suggest hat the appearance of 
PAI-I  activity after LPS stimulation plays a significant 
role in the pathogenesis of disseminated intravascular co- 
agulation (DIC) associated with septicemia. 
Fucoidan is a sulfated poly(L-fucopyranose) present in 
brown marine algae and has been reported previously to 
have anticoagulant activity in vitro and in vivo [3]. Our 
recent study has shown that the anticoagulant activity of 
this sulfated polysaccharide is improved by its further 
sulfation, and that the oversulfated fucoidan (OSF) is 
effective for the prevention of LPS-induced hepatic vein 
thrombosis in hyperlipemic rats [4]. We have also found 
that the fragments of OSF with little or no anticoagulant 
activity are effective for the prevention of thrombus forma- 
tion in the above model rats [5]. These results suggest hat 
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OSF and its fragments have another function(s), besides 
the regulation of blood coagulation. In this paper, we 
describe the suppressive ffects of OSF derivatives and 
heparin on LPS-induced release of PAI-I antigen from 
cultured human umbilical vein endothelial cells (HUVEC). 
We also present evidence that the HUVEC surface heparan 
sulfate proteoglycan (HSPG)-LPS interaction is an essen- 
tial prerequisite for the binding of LPS to the signal 
transducing receptor(s). 
times, 50 /zl of the conditioned media were removed and 
frozen at -80°C until use. Antigen levels of t-PA and 
PAl-1 (both complexed and free forms) in the conditioned 
media (20 /xl each) were measured with commercial en- 
zyme-linked immunosorbent assay (ELISA) kits, TintElize 
t-PA and TintElize PAI-1 (Biopool AB, Ume~, Sweden), 
respectively. 
2.4. IL-1/3 release from cultured HUVEC 
2. Materials and methods 
2.1. Materials 
IL- 1/3 antigen levels in the conditioned media (DMEM) 
were determined using a double antibody ELISA kit (Cay- 
man Chemical, Ann Arbor, MI). The minimal detectable 
concentration f IL- 1/3 was 1.5 pg/ml. 
The following materials were commercially obtained: 
Fucus vesiculosus fucoidan, porcine intestinal heparin and 
Escherichia coli LPS (serotype 0128:B 12) from Sigma; 
Flavobacterium heparinum heparitinase I and Proteus vul- 
garis chondroitinase ABC (protease free) from Seikagaku 
Corporation, Tokyo, Japan; mouse anti-HSPG monoclonal 
antibody (mAb) from Chemicon International, Temecula, 
CA, USA; recombinant human interleukin-I fl (IL- 1/3) 
from Boehringer Mannheim Biochemica, Tokyo, Japan; 
porcine skin type I collagen from the Nitta Gelatin, Osaka, 
Japan. 
2.2. HUVEC culture 
HUVEC (passage 2) and its culture medium (EGM- 
UV TM) were purchased from Kurabo Industries, Osaka, 
Japan. The cells (6 × 105 cells) were plated into a 175-cm 2
tissue culture flask (Falcon) and grown near to confluency 
in EGM-UV (modified MCDB 131 medium that was 
supplemented with 2% fetal calf serum, 10 ng/ml epider- 
mal growth factor, 1 /.tg/ml hydrocortisone, 50 /zg/ml 
gentamycin, 0.25 /zg/ml a photericin B, 10 /xg/ml hep- 
arin and 10 /xg/ml bovine brain extract) at 37°C in a 
humidified 5% CO 2 atmosphere. The medium was re- 
newed every 2 days. Subcultures were obtained by treating 
the HUVEC cultures with 0.05% trypsin/0.53 mM EDTA 
(GIBCO) at 37°C for 5 min. All experiments were per- 
formed with HUVEC in the 4th to 6th passages. Cell 
viability was evaluated by Trypan blue exclusion. 
2.3. t-PA and PAL1 antigen levels 
2.5. Treatment of HUVEC with heparitinase or chondroiti- 
nase 
When the cells in 6-well tissue culture plates were 
grown to confluency, the media (EGM-UV) were replaced 
with 2 ml of EGM TM (EGM-UV without heparin and 
bovine brain extract) containing 0.05 units/ml of hepariti- 
nase I or 0.5 units/ml of chondroitinase ABC. Incubation 
followed at 37°C for 16 h in a humidified 5% CO 2 
atmosphere. The HUVEC monolayers were washed exten- 
sively with DMEM, and incubation was continued with 3 
ml of DMEM, which, if indicated, contained 10/zg/ml of 
LPS. After 24 h, aliqouts (20 ~1) of the media were 
subjected to PAl-1 antigen assay. 
2.6. Treatment of HUVEC with HSPG mAb 
After removal of EGM-UV, the confluent HUVEC 
monolayers were treated at 37°C for 1 h with 1.5 ml of 
either DMEM alone or DMEM containing 4 /xg/ml of 
HSPG mAb, which specifically recognizes the core pro- 
tein. The wells were washed with DMEM and incubated in 
3 ml of DMEM with or without 10 /xg/ml of LPS at 37°C 
for 24 h. The conditioned media were removed, and the 
wells were extensively washed with DMEM. The HUVEC 
monolayers were then extracted at 37°C for 30 min with 1 
ml of 25 mM sodium phosphate buffer (pH 7.3)/0.15 M 
NaC1/0.5% Triton X-100. The cell lysates were cen- 
trifuged at 9000 X g for 10 min, and the supernatants were 
subjected to PAl-1 antigen assay together with the condi- 
tioned media. 
The passaged cells were seeded at a density of 5 X 10 3 
cells/cm 2 onto collagen-coated 6-well tissue culture plates 
(Falcon) in EGM-UV and allowed to reach confluency. 
After removal of the conditioned media, the HUVEC 
monolayers were rinsed twice with 5 ml of Dulbecco's 
modified Eagle's medium (DMEM). Incubation followed 
at 37°C in 3 ml of DMEM which, if indicated, contained 
either sulfated polysaccharide or LPS or both. At definite 
2.7. Preparation of OSF and its fragments 
Native fucoidan (200 mg) was purified on a Sephadex 
G-100 column (2.5 X 36 cm) equilibrated with 0.5 M 
NaC1. OSF with a molecular mass of 100-130 kDa was 
prepared as described previously [4]. Briefly, the purified 
fucoidan was further sulfated in a mixture of dimethyl- 
formamide and sulfur trioxide-trimethylamine complex at 
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50°C for 24 h. The product was recovered by ethanol 
precipitation and followed by purification on the Sephadex 
G-100 column. The yield of OSF was 144 mg; the sulfate 
content was estimated to be 52.4%. Fragmentation and 
sulfation of fucoidan were as described previously [5]. The 
purified fucoidan (300 mg) was dissolved in 12 ml of 0.5 
N H2SO 4 and heating followed in a sealed test tube at 
50°C for 4 h. After cooling, the solution was neutralized, 
dialyzed exhaustively against water and lyophilized. The 
residue (fragmented fucoidan) was suspended in l0 ml of 
dry dimethylformamide. The suspension was mixed with 
sulfur trioxide-trimethylanJne complex (667 mg) and al- 
lowed to react at 50°C :for 24 h. The products (OSF 
fragments) recovered by ,ethanol precipitation were dis- 
solved in 0.5 M NaCI anti fractionated on the Sephadex 
G-100 column. Fractions corresponding to 60-40, 40-20 
and 20-10 kDa molecular mass regions were pooled, 
concentrated on a YM-3 membrane (Amicon), and purified 
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Fig. 2. Concentration dependence of the sulfated polysaccharide suppres- 
sion of LPS-induced PAI-I antigen release. Confluent cultures of HU- 
VEC were incubated at37°C for 16 h in DMEM containing 10/.tg/ml of 
LPS without or with the indicated concentrations of native fucoidan ( r, ), 
OSF (•),  or heparin ([]). PAl-I antigen in the medium was measured as
described in Section 2. Each point represents he mean + S.E. of 
triplicate xperiments. 
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Fig. 1. Effects of LPS and its combination with sulfated polysaccharide 
on the release of PAI-I (panel A) and t-PA (panel B) antigens from 
cultured HUVEC. Confluent cukures of HUVEC in 6-well plates were 
incubated at37°C in DMEM with 10 ~g/ml LPS alone (0), 10 ~g/ml 
LPS plus 10 /~g/ml native fucoidan (zx), 10 /zg/ml LPS plus 10 
/.tg/ml OSF (A), 10 /zg/ml LPS plus 10 /~g/ml heparin (n)  or no 
addition (O). At the indicated times, 50 /xl of the conditioned medium 
was removed and subjected to beth PAI-1 and t-PA antigen assays. Each 
value is the mean of duplicate xperiments. 
on the same column. The yields of 10-20, 20-40 and 
40-60 kDa fragments were 29.5, 9.0, and 15.6 mg, respec- 
tively. 
3. Results 
3.1. Suppression of  LPS-induced HUVEC PAL1 release by 
OSF and heparin 
Fig. 1A shows the time course of LPS-induced PAI- I  
antigen release from cultured HUVEC and the effects of 
native and oversulfated fucoidans and heparin on the in- 
creased level of PAI-1. Conditioned medium derived from 
HUVEC that was incubated for 12-24 h in the presence of 
LPS (10 /zg /ml )  had a higher PAI-1 level than that from 
control culture (1.8 to 2.4-fold increase). However, the 
simultaneous presence of OSF or heparin (10 /xg/ml  
each) in conditioned medium maintained the release of 
PAI-1 antigen near to or under the control level over 24 h 
incubation. The ability of native fucoidan to reduce the 
LPS-stimulated PAI-1 release was negligible. On the other 
hand, neither LPS (10 /zg /ml )  alone nor its combination 
with each sulfated polysaccharide (10 /zg /ml )  influenced 
the release of t-PA antigen by cultured HUVEC (Fig. 1B). 
The concentration-dependent suppression of LPS-induced 
PAI-1 release by sulfated polysaccharide is shown in Fig. 
2. At a 16-h incubation of cultured HUVEC with 10 
/xg/ml  of LPS, the PAI-1 antigen levels (225 ___ 10.4 
ng /ml )  were 2.7-fold higher than the control levels (82 _+ 
4.5 ng/ml) .  The suppressive ffects of OSF and heparin 
were observed even at a concentration of I /xg/ml  (OSF, 
143+ 13.2 ng /ml ;  heparin, 165+ 13.2 ng /ml )  and 
reached maximum at 5 -10  /zg/ml .  On the other hand, the 
suppressive ffect of native fucoidan was small, but it 
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Fig. 3. Effects of various molecular sizes of OSF on the LPS-induced 
release of PAI-1 antigen from cultured HUVEC. Confluent cultures of 
HUVEC were incubated at 37°C for 16 h in DMEM without or with 10 
/zg/ml LPS alone or 10 /xg/ml LPS plus 10 /xg/ml OSF (fragment). 
PAI-1 antigen in the medium was measured asdescribed in Section 2. 
Each bar represents the mean + S.E. of triplicate experiments. 
decreased the increased PAl-1 levels in a concentration-de- 
pendent manner from 5 to 20 /xg /ml  (162 + 8.6 ng /ml  at 
a fucoidan concentration f 20 /zg/ml).  
3.2. Effects of molecular sizes of OSF on the suppression 
of LPS-induced HUVEC PAI-1 antigen release 
We next compared the suppressive ffects of OSF 
fragments (10-20, 20-40, and 40-60 kDa) with that of 
100-130 kDa form of OSF. As shown in Fig. 3, PAI-1 
antigen levels in the media from HUVEC that were incu- 
bated for 16 h with 10 /zg/ml  of LPS rose from 75 __+ 8.6 
ng /ml  (control levels) to 205_  13.5 ng /ml  (2.7-fold 
increase). No significant difference in the ability to sup- 
press the increased PAI-1 antigen levels was seen among 
these different molecular sizes of OSF fragments (10 
/zg/ml  each). 
3.3. Effects of OSFs and heparin on IL-1/3-induced release 
of PAI-1 antigen from cultured HUVEC 
Fig. 4 shows the time course of IL-1/3-induced release 
of PAl-1 antigen from cultured HUVEC and the effects of 
100-130 and 20-40 kDa forms of OSF and heparin on the 
increased PAI-1 level. During the first 8 h of incubation 
with 10 units (200 ng) /ml  of IL-1/3, no significant in- 
crease over control level of PAI-1 antigen was observed. 
However, at 20 h, PAI-1 antigen level in the medium from 
IL-I/3-treated HUVEC was approx. 2.4 times that in con- 
trol medium (IL-l/3-treated HUVEC, 191 ng /ml ;  un- 
treated HUVEC, 82 ng/ml) .  Neither OSFs nor heparin (10 
~g/ml  each) could suppress the increased level of PAl-1. 
3.4. IL-1 production by cultured HUVEC 
Because HUVEC can synthesize IL-1 [6] and the syn- 
thesis is increased by LPS [7], we determined IL-I antigen 
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Fig. 4. Effects of sulfated polysaccharides on the IL-1/3-induced release 
of PAI-1 antigen from cultured HUVEC. Confluent cultures of HUVEC 
were incubated at 37°C in DMEM with 10 units/ml IL-I/3 alone (0), 10 
units/ml IL-I/3 plus 100-130 kDa OSF (A), 10 units/ml IL-1/3 plus 
20-40 kDa OSF fragment (,x), 10 units/ml IL-1/3 plus heparin ([]) or 
no addition (©). At the indicated times, 50/zl of the conditioned medium 
was removed and subjected toPAI-1 antigen assay. Each value is the 
mean of duplicate experiments. 
levels in the media from HUVEC that were incubated for 
24 h in the presence or absence of 10 /.tg/ml of LPS, 
using IL-1/3 ELISA kit. The result indicated that in these 
experimental conditions the cultured HUVEC did not re- 
lease IL-1 in response to LPS stimulation or that the 
released IL-1 antigen was not detectable (under 1.5 pg/ml )  
by the ELISA method (data not shown). 
3.5. Effect of heparitinase or chondroitinase treatment on 
the LPS-induced PAI-1 antigen release 
Confluent HUVEC cultures were treated with or with- 
out 0.05 uni ts /ml  of heparitinase I or 0.5 units/ml  of 
Addltlon 
.o.e ~ / / ~  Control 
plus LPS ~ ~ / ~  
none ~/ /~ Heparltimme 
Treatment 
none ~ Chondroltlnmm 
Tmammtt 
0 50 100 150 200 250 
PAl-1 Antigen (ng/ml) 
Fig. 5. Effect of  hcparitinasc or chondroitinase ABC treatment on the 
LPS-induced release of PAI-I antigen from cultured HUVEC. Confluent 
cultures of HUVEC were incubated at 37°C for 16 h in EGM without or 
with 0.05 units/ml heparitinase or 0.5 units/ml chondroitinase ABC. 
After washing with DMEM, the HUVEC monolayers were exposed to 
LPS (10 /zg/ml) for 24 h. Aliquots (20 /zl) of the conditioned medium 
were subjected to PAI-1 antigen assay. Each bar represents the mean + S.E. 
of triplicate experiments. 
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chondroitinase ABC at 37°C for 16 h. The cells were then 
washed and incubated with LPS (10 /zg/ml) at 37°C for 
24 h. As shown in Fig. 5, the release of PAI-1 antigen 
from glycosaminoglycanase-untreated HUVEC was in- 
creased approx. 2.7-fold (78_  5.4 ng/ml  vs. 214_  14.5 
ng/ml)  in response to the LPS stimulation. Treatment of 
cultured HUVEC with heparitinase r sulted in a significant 
decrease (88_  10.2 ng/ml)  in the LPS-induced PAI-1 
accumulation i medium. Heparitinase treatment i self did 
not affect the ability of HUVEC to release PAl-1 antigen 
in the medium (74 _ 4.8 ng/ml). Inactivation of the hepar- 
itinase activity by heat treatment (80°C, 30 min) abolished 
the ability of this enzyme to decrease the HUVEC re- 
sponse to LPS (data not shown). On the other hand, 
chondroitinase ABC treatment had no effect on the release 
of PAI-1 antigen from LPS-untreated HUVEC (68 ___ 6.2 
ng/ml). The HUVEC response to LPS was only slightly 
reduced by this enzyme treatment (185 _ 10.3 ng/ml). 
3.6. Treatment of cultured HUVEC with HSPG mAb 
The HUVEC grown to confluency were treated at 37°C 
for 1 h with DMEM alone or DMEM containing 4 ~g/ml  
of mAb, which specifically recognizes the protein core of 
HSPG. The cells were then washed and incubated at 37°C 
for 24 h in the presence or absence of 10 ~g/ml  of LPS. 
PAI-I antigen levels in both the conditioned media and the 
cell lysates are shown in Table 1. The PAI-1 release by 
HSPG mAb-untreated HUVEC rose from 55 _ 4.3 ng/ml  
to 193_ 9.8 ng/ml  (approx. 3.5-fold increase) by the 
exposure to LPS for 24 h. The PAI-I levels in the cell 
lysates were also increased approx. 2 times by the LPS 
stimulation (13 _ 1.6 ng/ml  vs 26_  5.8 ng/ml). How- 
ever, the PAI-1 release by HSPG mAb-treated HUVEC 
was not enhanced by the LPS stimulation (62 ___ 3.6 ng/ml  
vs 51 -t-5.6 ng/ml), and the PAI-1 content of the cell 
lysate was almost the same as that of control (10_  0.4 
ng/ml  vs 12 _+ 1.1 ng/ml). 
Table 1 
Effect of HSPG mAb treatment on LPS-induced HUVEC PAI-I antigen 
release 
Treatment LPS stimulation PAI-1 antigen 
Medium Cell lysate 
(ng/ml) (ng/ml) 
None - 55+4.3 13+ 1.6 
+ 193+9.8 26+0.8 
HSPG mAb - 62+3.6 12_+ 1.1 
+ 51+5.6 10-t-0.4 
Confluent cultures of HUVEC were incubated at 37°C for 1 h in DMEM 
with or without 4/.tg/ml of HSPG mAb. After washing with DMEM, the 
HUVEC monolayers were exposured to LPS (10 ~g/ml)  for 24 h. The 
cell lysates were prepared as described in Section 2. Each value repre- 
sents the mean _+ S.E. of triplicate experiments. 
4. Discussion 
The data shown in Fig. 1 confirmed previous reports 
[1,2] that the treatment of cultured HUVEC with LPS 
induces a specific production of PAI-1 without altering 
t-PA level. Although it has been speculated that the net 
decrease of the fibrinolytic potency in blood stream may 
contribute to the pathogenesis of DIC associated with 
septicemia, the precise mechanisms by which the endo- 
toxic LPS causes endothelial cell injury remains unclear. 
The present study demonstrated that OSF and heparin 
could greatly reduce the LPS-induced release of PAI-1 
antigen from cultured HUVEC (Fig. 1A). The suppressive 
effects of both sulfated polysaccharides were concentra- 
tion-dependent. Native fucoidan also showed a concentra- 
tion-dependent suppression, but the effect was very small 
(Fig. 2). We prepared OSF fragments with various molecu- 
lar sizes (10-20, 20-40 and 40-60 kDa) and examined 
their abilities to suppress the LPS-induced PAI-I antigen 
release. The result indicated that these OSF fragments 
were effective as well as the 100-130 kDa form of OSF 
(Fig. 3). Native fucoidan is a polymer of L-fucose, having 
a sulfate group on either C 3- or Ca-position of the fucose 
unit [3]. OSF and its fragments have sulfate groups on both 
positions. Therefore, the degree of sulfation, namely, a 
particular spatial orientation of the negative charges in 
these fucoidan molecules may be an important determinant 
for their effectiveness. However, it remains to be deter- 
mined whether the spacial orientation of the sulfate groups 
of OSFs is similar to that of another potent inhibitor, 
heparin. 
Several cytokines, such as tumor necrosis factor-a [8], 
transforming rowth factor-fl [9] and IL-lt~ and - l f l  
[10-12], stimulate the PAI-1 production by cultured en- 
dothelial cells. Emeis and Kooistra [10] suggest that IL-1 fl 
is a better inducer of PAI-1 production than IL-1 c~. Also, 
the IL-1 synthesis of endothelial cells is increased by LPS 
[7], suggesting a possibility that LPS acts by way of the 
increased secretion of IL-1. Determination of IL-1/3 anti- 
gen levels in the media from LPS-stimulated and unstimu- 
lated HUVEC revealed that the concentrations of IL-1/3 
were under 1.5 pg/ml  (data not shown). However, exoge- 
nously added IL-1/3 (200 ng/ml)  stimulated the PAI-1 
antigen release by 2.4-fold at 20 h of incubation. Neither 
100-130 and 20-40 kDa OSFs nor heparin could suppress 
the increased PAI-1 level (Fig. 4). Thus, at least in our 
experimental conditions, the PAI-1 production enhanced 
by LPS may be linked with another induction 
mechanism(s). 
A growing possibility is that OSFs and heparin may 
suppress the LPS-induced PAI-I antigen release by pre- 
venting the binding of LPS to a certain HUVEC surface 
molecule, which structurally resembles these sulfated poly- 
saccharides. Our prospect was that HSPG might serve at 
least as the initial binding site on the cell surface. Indeed, 
treatment of cultured HUVEC with heparitinase r sulted in 
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a significant loss of the ability to enhance PAI-1 release in 
response to LPS stimulation (Fig. 5). Chondroitinase ABC 
treatment hardly affected the susceptibility of HUVEC to 
LPS. The results suggest hat heparitinase-sensitive sit s 
on the HUVEC surface play an important role in the 
LPS-induced enhancement of PAI-I release. To confirm 
whether these molecules are HSPG, cultured HUVEC was 
treated with an mAb, which specifically recognizes the 
protein core of HSPG (Table 1). The mAb treatment 
resulted in a complete loss of HUVEC susceptibility to 
LPS on the PAI-1 release, indicating the active role of 
HSPG. To our knowledge, a part of the secreted PAI-1 
accumulates in the extracellular matrix [13]. Determination 
of the amount of PAI-I in the cell lysates from HSPG 
mAb-untreated HUVEC revealed that the LPS-induced 
enhancement of PAI-I release was accompanied with the 
increased accumulat ion  of the extracel lu lar  
(membrane/matrix-bound) and/or intracellular PAl-1 (2- 
fold increase). In the cell lysates derived from HSPG 
mAb-treated HUVEC, the PAl-1 content did not change to 
LPS stimulation. The direct binding of mAb to HSPG on 
the cell surface altered neither the levels of PAI-1 release 
nor the intracellular PAI-1 content. Therefore, it seems 
unlikely that HSPG can function by itself as the signal 
transducing receptor for increased PAl-1 production. The 
HSPG and LPS interaction may be an essential pre- 
requisite for the binding of LPS to the receptor(s). How- 
ever, it remains unclear how LPS binds to HSPG. The 
observed suppressive ffects of OSF and heparin may 
result from the prevention of LPS binding to the sugar 
chain of HSPG. In that case, the binding of mAb to the 
core protein of HSPG may contribute to the masking of the 
heparan sulfate side chains. 
Our previous tudy [5] has demonstrated that the 20-40 
kDa OSF fragment with little or no anticoagulant activity 
in vitro is effective for the prevention of LPS-induced 
hepatic vein thrombosis in hyperlipemic rats. From the 
present results, the ability of this OSF fragment o effec- 
tively suppress the LPS-induced enhancement of endothe- 
lial PAI-1 release might contribute to the prevention of 
damaging endothelium and local thrombus formation in 
the LPS-treated rats. Patients with DIC are reported to 
have greatly elevated levels of circulating hyaluronic acid 
that binds to fibrinogen and enhances clot formation [14]. 
OSF, unlike heparin, has the ability to reduce the hyaluronic 
acid-induced enhancement of fibrin clot formation [4]. 
Therefore, further studies addressing the potential ability 
of OSFs to regulate blood coagulation and fibrinolysis and 
the precise mechanism(s) by which the sulfated fucose 
polymer prevents the endotoxin binding to vascular en- 
dothelium may provide useful clues for the development of
an ideal therepeutic agent for the endotoxic LPS-induced 
DIC. 
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